GlassScriptPhysician profile
Alessandra Ferrera
NPI 1730676248
$4,990.06
in general payments reported to CMS, 2019-2025
24 companies · $90.77 in 2025
The $90.77 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2021: $228 · 2022: $686 · 2023: $2,184 · 2024: $1,689 · 2025: $90.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $697.17 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $637.58 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $538.71 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $494.48 | 2022-2024 | Spravato |
| Abbvie INC. | $390.74 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $346.26 | 2019-2024 | Ingrezza |
| Almatica Pharma LLC | $293.17 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $285.43 | 2022-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $232.35 | 2022-2024 | Trintellix |
| Lundbeck LLC | $169.19 | 2022-2024 | Rexulti |
| Corium, LLC | $165.56 | 2023-2025 | Azstarys |
| Bausch Health US, LLC | $157.25 | 2022-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $108.52 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $85.63 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $67.14 | 2024 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $53.00 | 2024 | Auvelity |
| Ucb, INC. | $49.17 | 2022 | |
| Ironshore Pharmaceuticals INC. | $39.30 | 2022-2024 | |
| Noven Therapeutics, LLC | $37.89 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $35.38 | 2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $35.24 | 2024 | Hetlioz, Fanapt |
| Tempus Ai, INC | $27.95 | 2024 | |
| Avanir Pharmaceuticals, INC. | $25.43 | 2022 | |
| Livanova USA, INC. | $17.52 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alessandra Ferrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.